Our previous work [36] in breast cancer patients has clearly demonstrated that such DCTs and DCTIs have an optimal antigen uptake capacity and upregulation of CD86, CD40 and class I, but low levels of CD83, as is expected of non-terminally mature DCs. This evidence concerns the gene CD86 and breast cancer.